Response to: Comment on “A comparative study of once-daily versus twice-daily tacrolimus in deceased donor kidney transplant recipients: a national cohort analysis”
Authors:
- Bekir TanrioverBTBekir Tanriover
- Gaurav GuptaGGGaurav Gupta
- Ahmet B. GungorAGAhmet B. Gungor
- 17 October 2026
- journal article
- Published by Elsevier in American Journal of Transplantation
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Comment on “A comparative study of once-daily versus twice-daily tacrolimus in deceased donor kidney transplant recipients: A national cohort analysis”American Journal of Transplantation, 2026
- A comparative study of once-daily vs twice-daily tacrolimus in deceased donor kidney transplant recipients: a national cohort analysisAmerican Journal of Transplantation, 2026
- Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trialPLOS Medicine, 2017
- A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover StudyAmerican Journal of Transplantation, 2017
- Introduction to the Analysis of Survival Data in the Presence of Competing RisksCirculation, 2016